Shares of Amicus Therapeutics (FOLD) have gained 12.9% over the past four weeks to close the last trading session at $6.83, ...

Amicus Therapeutics (FOLD) could be a solid choice for investors given the company's remarkably improving earnings outlook.

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...

Amicus Therapeutics (NASDAQ:FOLD) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

An Amicus Therapeutics combination treatment for the rare enzyme deficiency Pompe disease now has FDA approval, giving the drugmaker the opportunity to help patients who don’t respond to Sanofi ...

Amicus Therapeutics (NASDAQ: FOLD) has significantly transformed over the last few years. From a company with an uncertain regulatory status of its lead product (Galafold) and a young and not too ...

For the quarter, Amicus generated $2.1 million in product revenue, which is up from zilch last year, when it had no products on pharmacy shelves, and a net loss of $46.7 million, or $0.33 per ...

PHILADELPHIA, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines ...

So what For the quarter, Amicus generated $2.1 million in product revenue, which is up from zilch last year, when it had no products on pharmacy shelves, and a net loss of $46.7 million, or $0.33 ...